Rockwell Medical, Inc. · NASDAQ:RMTI

Rockwell Medical — Investor Presentation (November 2023)

18 slides from Rockwell Medical's investor presentation, Nov 14, 2023

  1. Slide 1: Investor Presentation

    (© ROCKWELL MEDICAL Investor Presentation November 14, 2023 RMTI Nasdaq Listec

  2. Slide 2: Forward-Looking Statements and Non-GAAP Measures

    Forward-Looking Statements and Non-GAAP Measures Certain statements in this presentation may constitute "forward-looking statements” within the meaning of federal securities laws, including, but not limited to, Rockwell's expectations regarding revenue, profitability, financial position, 2023 guidan

  3. Slide 3: Rockwell Medical At A Glance

    Rockwell Medical At A Glance Healthcare company that develops, manufactures, commercializes, and distributes a hemodialysis products for dialysis providers worldwide. . Second largest supplier of acid and bicarbonate concentrates for dialysis patients in the U.S. Business Leeicld : ae Overview Restr

  4. Slide 4: Executive Management Team

    Executive Management Team Mark Strobeck, Ph.D. President and CEO Aqu JO =—-Assertic= Tim T. Chole SVP, Sales and Marketing Baxter ( Cote o "GAMBRO. Watson Pharmaceuticals’ Jesse Neri SVP, Finance ARUVANT ae Symphony Health Zyl a» © 2023 Rockwell Medical, Inc. Megan Timmins EVP, Chief Legal Officer a

  5. Slide 5: Corporate Strategy

    Corporate Strategy QO) Be the Global Leader in Hemodialysis Concentrates O) Provide Customers with the Highest Quality and Most Reliable Products and Services QO) Achieve Profitability and $100M+ Annual Net Sales O) Focus on Innovative, Long-Term Growth Opportunities © 2023 Rockwell Medicale. QROCKW

  6. Slide 6: Hemodialysis overview

    * Procedure whereby a dialysis machine and a special filter called an artificial kidney — or dialyzer — are used to clean a patient’s blood. ¢ Filters out wastes, salts, and excess fluid, and corrects electrolyte and acid-base imbalances for people who have kidney failure, or end-stage kidney diseas

  7. Slide 7: U.S. In-Center Hemodialysis Concentrates Market

    U.S. In-Center Hemodialysis Concentrates Market Estimated growth driven primarily by increasing number of patients suffering from end-stage kidney disease TODAY 2026 SOURCE: “Rockwell Medical: Concentrates Growth Strategy Report”, LE.K. Consulting LLC (2022) fy RMT! © 2023 Rockwell Medial, ne ©ROCKW

  8. Slide 8: Indispensable Player in Large, Expanding Market

    Indispensable Player in Large, Expanding Market * Rockwell Medical is one of two manufacturers and suppliers that has scalability and transportation infrastructure to service the more than 12,000 individual purchasing facilities (including outpatient dialysis clinics and hospitals) in the U.S., alon

  9. Slide 9: Potential Growth Opportunities and Revenue Streams

    Potential Growth Opportunities and Revenue Streams Geographic Expansion Rockwell continues to increase its market share in Western U.S. and internationally Signed Co-Promotion Agreement with B. Braun, targeting customers in the West Acquired hemodialysis concentrates business from Evoqua Water Techn

  10. Slide 10: Acquired Hemodialysis Concentrates Business from Evoqua

    Acquired Hemodialysis Concentrates Business from | eVvoauA Background Value Add Terms * Profitable, fully automated concentrates business ia 5 * Generated annual revenue of and dialysis patients §18M and $3.3M in EBITDA throughout the U.S. Bat di ‘ immediately accretive * With synergies, Rockwell ex

  11. Slide 11: Rockwell Medical Expands Distribution Footprint in the U.S.

    Rockwell Medical Expands Distribution Footprint in the U.S. * Acquired Evoqua’s hemodialysis concentrates customer contracts ¢ Added an additional estimated 1,700 clinics in the U.S. * Rockwell Medical now the leading supplier of liquid bicarbonate products in the U.S. Pre-Acquisition Post-Acquisiti

  12. Slide 12: Financials and Milestones

    (©) ROCKWELL MEDICAL Financials and Milestones

  13. Slide 13: Delivering on New Business Strategy

    Delivering on New Business Strategy Increasing revenue, reducing expenses, driving the Company towards profitability on an Adjusted EBITDA basis Three Months Ended Nine Months Ended September 30 September 30 tnt a ee as ee Net Sales 23,771 18,691 61,519 53,497 Gross Profit $ 2,202 S 777 $ 5,834 $ 1,

  14. Slide 14: Focused on Driving Business to Profitability in Q4'23

    Focused on Driving Business to Profitability in Q4’23 .. along with revenue growth, reducing expenses and paying down debt (sm) (sm) 8.0- 10.0 - 10 85 Ca 86.0 ; a 21.6 80 20 15 a 72.8 10.0 70 10 8.0 5 65 2.0 = L E lam__° 60 Re ee 2021 2022 2023 GUIDANCE GUIDANCE Ye21 = -YE'220YE'23.-YE'24 (3/16/25 *

  15. Slide 15: Projected Milestones for 2023

    Projected Milestones for 2023 Complete 100% Transfer of Baxter Business with Preferred Economics Expand Partnerships with Existing Hemodialysis Customers Grow Concentrates Business by Adding New Customers Distribute Hemodialysis Products in New Geographies Complete Integration of Evoqua’s Hemodialys

  16. Slide 16: Why Invest in Rockwell Medical?

    Why Invest in Rockwell Medical? UO) Revenue-Generating Business O) Large and Growing Market Opportunity LISTING ANNIVERSApy O) Path to Profitability in Q4’23 ) ROCKWELL. O) Strengthened Financial Position MEDICA, Q) Attractive Valuation RMTI NasdagqListed © 2023 Rockwell Medicale. QROCKWELL ZA MEDIC

  17. Slide 17: MEDICAL

    ©) ROCKWELL MEDICAL www.rockwellmed.com IR@rockwellmed.com

  18. Slide 18: Reconciliation to GAAP Financial Measures

    Reconciliation to GAAP Financial Measures Non-GAAP Financial Measures To supplement the Company's financial results presented on a U.S. generally accepted accounting principles ("GAAP") basis, the Company has included information about non-GAAP measures of EBITDA and adjusted EBITDA as useful operat

Rockwell Medical — Investor Presentation (November 2023) on 6ix